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Abstract: BACKGROUND In recent years, non-vitamin K antagonist (VKA) oral anticoagulants (NOACs)
have been increasingly prescribed to adults with congenital heart disease (CHD) and atrial arrhythmias
without good evidence for either safety or efficacy. To address this gap, we initiated an ongoing prospec-
tive global registry (NOTE: non-vitamin K antagonist oral anticoagulants for thromboembolic prevention
in patients with congenital heart disease). Using the NOTE registry data, the present study aimed to
evaluate the occurrence of any adverse events during the initiation phase (first 30 days) of NOACs in
adults with CHD and atrial arrhythmias. METHODS AND RESULTS For this prospective observational
study, 99 adults with CHD and atrial arrhythmias (median age 49 years [IQR 38-61], 53% male) who
initiated NOACs at or after the inclusion point were analysed. Thromboembolic events, major bleeding
and other minor adverse events were assessed after the first 30 days since the initiation of NOACs. In
54 patients transitioning from VKA to NOACs, 8 minor adverse events (5 minor bleeding; 3 side-effects;
1 drop-out due to minor bleeding) occurred within 30 days after the transition. No adverse events were
reported in 46 VKA-naive patients within 30 days after the initiation of NOACs. CONCLUSIONS Ini-
tiation of NOACs and transition from VKA to NOACs seem to be safe during the first month, without
major adverse events and with only limited minor side effects in adults with CHD and atrial arrhythmias.
This global ongoing prospective registry enables precise collection of important clinical information in
real-world adults with CHD, managed with NOACs.
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Abstract
Background In recent years, non-vitamin K antagonist
(VKA) oral anticoagulants (NOACs) have been increasingly
prescribed to adults with congenital heart disease (CHD) and
atrial arrhythmias without good evidence for either safety or
efficacy. To address this gap, we initiated an ongoing prospec-
tive global registry (NOTE: non-vitamin K antagonist oral
anticoagulants for thromboembolic prevention in patients
with congenital heart disease). Using the NOTE registry data,
the present study aimed to evaluate the occurrence of any
adverse events during the initiation phase (first 30 days) of
NOACs in adults with CHD and atrial arrhythmias.
Methods and Results For this prospective observational study,
99 adults with CHD and atrial arrhythmias (median age 49
years [IQR 38-61], 53% male) who initiated NOACs at or
after the inclusion point were analysed. Thromboembolic
events, major bleeding and other minor adverse events were
assessed after the first 30 days since the initiation of NOACs.
In 54 patients transitioning from VKA to NOACs, 8 minor
adverse events (5 minor bleeding; 3 side-effects; 1 drop-out
due to minor bleeding) occurred within 30 days after the tran-
sition. No adverse events were reported in 46 VKA-naive
patients within 30 days after the initiation of NOACs.
Conclusions Initiation of NOACs and transition fromVKA to
NOACs seem to be safe during the first month, without major
adverse events and with only limited minor side effects in
adults with CHD and atrial arrhythmias. This global ongoing
prospective registry enables precise collection of important
clinical information in real-world adults with CHD, managed
with NOACs.
Keywords Congenital heart disease . Atrial arrhythmia .
Anticoagulation . Non vitamin K antagonist oral
anticoagulant . Thromboembolic event . Bleeding
Introduction
Atrial arrhythmias are prevalent in 15% of adults with con-
genital heart defects (CHD) and are associated with increased
risk for thromboembolism [1]. The most recently introduced
oral anticoagulants, non-vitamin K antagonist oral anticoagu-
lants (NOACs) have been shown to be associated with an
equal or reduced risk for thromboembolism and major bleed-
ing compared with vitamin K antagonist (VKA) in the general
population with non-valvular atrial arrhythmias [2]. However,
it is uncertain whether results from that population are appli-
cable in CHD patients, since hearts of CHD patients are struc-
turally different. Nevertheless, NOACs are attractive alterna-
tives for VKA in this group of predominantly young patients,
as they may be compromised in their daily life by ongoing
international normalized ratio (INR) monitoring and dose ad-
justments. To date, few data have been published on the rates
of thromboembolism and major bleeding under the use of
NOACs in adults with CHD with atrial arrhythmias [3]. The
utility of these data are hampered by a limited sample size and
a short follow-up period.
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Accordingly, safety of NOACs needs to be assessed in
adults with CHD. For this purpose, we initiated a worldwide
prospective registry of efficacy and safety of non-vitamin K
antagonist oral anticoagulants for thromboembolic prevention
in patients with congenital heart disease; NOTE registry
(https://note.reports.nl; ClinicalTrials.gov registration:
NCT02928133). We present our first data on the safety of
initiation of NOACs and transition from vitamin K
antagonists to NOACs during the first 30 days in adult CHD
patients with atrial arrhythmias.
Methods
In the NOTE registry, adults with CHD using NOACs for
thromboembolic prevention have been enrolled from April
2014 onward. The NOTE study protocol conforms to the eth-
ical guidelines of the 1975 Declaration of Helsinki and was
approved by research committees of all participating medical
centres. Informed consent was obtained from all individual
participants included in the study.
This is a prospective cohort study, using data obtained from
the NOTE registry. We analysed all patients using NOACs for
atrial arrhythmias. We excluded the patients who initiated
NOACs prior to the time of enrolment or used NOACs for
other indications than atrial arrhythmias. The patients were
included as they presented at the participating institutions or
were identified by using a national registry. The choice of
NOAC type was at the discretion of the patient’s cardiologist
without a specific protocol. At inclusion, demographics and
pre-defined clinical data were collected. The time period of
evaluation of the safety of NOACs initiation was set as within
30 days after the initiation of NOACs. Follow-up took place at
180 ± 28 days, 1 year ±28 days, and 2 years ±28 days, coin-
ciding with their routine outpatient clinical visit or telephone
contact. At such follow-up point, evaluation of pre-defined
end points was conducted by an investigator or a site coordi-
nator, who was trained on the protocol of the NOTE registry.
The major adverse events were thromboembolism (ischemic
cerebrovascular accident iCVA, transient ischemic attack TIA,
systemic or pulmonary embolism or intracardiac thrombosis)
and major bleeding (significant bleeding necessitating hospi-
talization/interventions/≥2 units of packed cells, and/or with a
haemoglobin drop >1.24 mmol/L and/or bleeding that was
fatal or occurred in the following critical sites: intra-cranial,
intra-spinal, intra-ocular, pericardial, intra-articular, intra-
muscular with compartment syndrome) according to the
International Society on Thrombosis and Haemostasis criteria
[4]. As secondary endpoints, we registered other adverse
events (minor bleeding event, mortality, hospitalization,
interventions).
The VKA-experienced group consisted of the patients who
used VKA at the time of transitioning to NOAC. The rest of
the group was defined as the VKA-naive group. Any differ-
ences between the VKA-experienced group and VKA-naive
group, and between the group with minor bleeding and the
group without minor bleeding were analysed using unpaired t-
tests and reported as median with IQR or frequencies in % as
appropriate. Analyses were performed with SPSS version
21.0 (IBM Corp., Armonk, NY, USA). A p-value below
0.05 was considered statistically significant.
Results
Through collaboration with the International Society for Adult
Congenital Heart Disease (ISACHD), there are currently 31
participating medical institutions worldwide and enrolment
has started in 26 of these institutions for this ongoing multi-
center prospective registry. So far, 245 adults using NOACs
were recruited in the NOTE registry.
For the present study, 146 patients were excluded from the
analysis according to the exclusion criteria. A total of 99
adults (Table 1; median age 49 years [IQR 38–61], 53%male)
represent the study cohort for this analysis. The cohort con-
sists of a wide variety of CHD types (Fig. 1; complex 29%,
moderate 56%, simple 15%). At the time of transition to
NOACs (=baseline), 41% of the patients were not on any
anti-thrombotic therapy, 4% were on aspirin and 55% used
VKA (2 patients concomitant aspirin; median treatment peri-
od 7.7 years [IQR 2.5–10.6]). All patients started NOACs
(apixaban 62%; rivaroxaban 29%; dabigatran 9%) for atrial
arrhythmias. The most common types of atrial arrhythmias
were atrial fibrillation (60%) and atrial flutter or intra atrial
re-entry tachycardia (44%). Regarding the CHA2DS2-VASc
and HASBLED score, 57% and 88% of the patients had a
score of 0 or 1, respectively. Overall, 11% had Fontan circu-
lation (atriopulmonary connection n = 6; lateral tunnel or in-
tracardiac conduit n = 4; extracardiac conduit n = 1), 7%
pulmonary hypertension and 33% had a history of heart fail-
ure defined by clinical signs or low systolic function by im-
aging (Table 1). Twelve percent of the patients previously
experienced an iCVA or TIA, 3% deep venous thrombosis,
3% intracardiac thrombosis, 2% pulmonary embolism, 1%
myocardial infarction, and 9% had prior major bleeding.
Compared with the VKA-naive group, the VKA-
experienced group had higher HASBLED score (median 0
[IQR 0–1] vs. 1 [IQR 0–1], p = 0.002) and higher prevalence
of prior major bleeding (2.2% vs. 14.8%, p = 0.030).
Regarding the safety during the first 30-day follow-up after
initiation of NOACs, none of the patients experienced a
thromboembolic event or a major bleeding complication, ei-
ther in the VKA-naive group or in the VKA-experienced
group. In the VKA-experienced group (n = 54), 9% of the
patients reported minor bleeding, most often epistaxis
(n = 3), hematoma (n = 1) and gingival bleeding (n = 1), within
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the first 30 days after the transition. Due to frequent epistaxis, a
42-year old female with coarctation of the aorta, ceased NOAC
therapy within 30 days and switched back to VKA. Other side
effects such as dizziness, headaches, nausea andweakness were
also reported (n = 3) in this group. All patients who reported
minor adverse events (n = 8) were in the VKA-experienced
group and were relatively young (< 65 yr) and had moderate
or severe CHD; none had a Fontan circulation. No adverse
events were reported by patients in the VKA-naive group
(n = 45). The prevalence of higher HASBLED score (≥2) was
similar between the group with minor bleeding and the group
without minor bleeding (12.8% vs. 0%, p = 0.394).
Discussion
Initiation of NOACs and transition from VKA to NOACs
appeared to be safe for at least the short-term, without major
Table 1 Baseline characteristics
All (n = 99) VKA (n = 54) VKA-naive (n = 45) p-value
Age at inclusion, y 48.8 (38–61) 47.3 (38–61) 52.0 (37–61) 0.784
Male, n(%) 52 (53) 24 (44) 28 (62) 0.078
Severity of congenital heart defect, n (%)
Simple 15 (15) 8 (15) 7 (16) 0.918
Moderate 55 (56) 28 (52) 27 (60) 0.417
Complex 29 (29) 18 (33) 11 (24) 0.333
Fontan circulation 11 (11) 9 (17) 2 (4) 0.054
Pulmonary hypertension 7 (7) 3 (6) 4 (9) 0.519
Median CHA2DS2-VASc 1 (0–2) 1 (0–2) 1 (0–2.5) 0.632
Median HASBLED 0 (0–1) 1 (0–1) 0 (0–1) 0.002
Cardiovascular history, n(%)
Stroke or TIA 12 (12) 7 (13) 5 (11) 0.779
Pulmonary embolism 2 (2) 1 (2) 1 (2) 0.941
Deep venous thrombosis 3 (3) 1 (2) 2 (4) 0.454
Intracardiac thrombosis 3 (3) 3 (6) 0 0.095
Myocardial infarction 1 (1) 1 (1) 0 0.359
Major bleeding 9 (9) 8 (15) 1 (2) 0.030
Heart failure* 33 (33) 20 (37) 13 (29) 0.392
Hypertension 24 (24) 11 (20) 14 (30) 0.319
Diabetes mellitus 8 (8) 4 (7) 4 (9) 0.788
Values are presented as median (IQR) or counts(%). *Heart failure is defined as the presence of signs and
symptoms of either right (elevated central venous pressure, hepatomegaly, dependent oedema) or left ventricular
failure (exertional dyspnoea, cough, fatigue, orthopnoea, paroxysmal nocturnal dyspnoea, cardiac enlargement,
crackles, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measure-
ments demonstrating objective evidence of cardiac dysfunction
Abbreviations: VKA, vitamin K antagonist-experienced group; VKA-naive, vitamin K antagonist naive group;
CHA2DS2-VASc, stroke risk factor scoring system in which 1 point is given for heart failure, hypertension, age
64–74 years, diabetes mellitus, history of vascular disease, female sex and 2 points are given for age ≥ 75 years,
history of stroke/TIA/thromboembolism; HASBLED, bleeding risk factor scoring system in which 1 point is
given for uncontrolled hypertension, abnormal renal or liver function, history of stroke or bleeding, labile inter-
national normalized ratio, age > 65 years, use of nonsteroidal anti-inflammatory drug or antiplatelet agents or
alcohol; NOAC, new oral anticoagulant; TIA, transient ischemic attack
Fig. 1 Distribution of congenital heart defects. Abbreviations: ToF-
tetralogy of Fallot; ASD-atrial septal defect; Fontan-Fontan circulation;
VSD-ventricular septal defect; TGA-transposition of the great arteries;
PS-pulmonary valve stenosis; CoA- aortic coarctation; AVSD-
atrioventricular septal defect; Ebstein-Ebstein’s anomaly; Other- double-
outlet right ventricle, pulmonary atresia, bicuspid aortic valve, Marfan
syndrome; ccTGA-congenitally corrected transposition of the great
arteries; CT-cor triatriatum
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adverse events and with limited minor side effects in 99 adults
with CHD and atrial arrhythmias.
Current guidelines state that NOACs are only considered in
patients with a simple form of CHD due to lack of data in
patients with moderate or complex forms of CHD [5]. Our
findings show reassuring short term safety results in a cohort
largely consisting of moderate or complex forms of CHD
(85%), including patients with Fontan circulation (11%) who
are prone to thromboembolism and bleeding. This result may
be due to the low median CHA2DS2-VASc score, HASBLED
score and young age in this cohort. Furthermore, recent stud-
ies showmixed results on the validity of CHA2DS2-VASc and
HASBLED scores in adults with CHD and atrial arrhythmias
[6, 7]. However, due to the presence of their structural heart
defects, adults with CHD are considered to have other risk
factors for stroke than just the CHA2DS2-VASc score.
Notably, all patients with minor adverse events were VKA-
experienced and had moderate to severe type of CHD. This
may be related to the higher HASBLED score and higher
prevalence of prior major bleeding in the VKA-experienced
group compared with the VKA-naive group. However, a
higher HASBLED score (≥2) at baseline was not related to
higher minor bleeding risk during the follow up.
This study is limited by the modest sample size, number of
events over a short-term follow-up and the observational de-
sign. Therefore, the data should be interpreted with caution
pending validation in other cohorts with larger sample sizes.
Furthermore, due to the low number of events in this study, we
were unable to perform regression analysis to determine
whether CHD complexity is a predictor of adverse events.
We expect to address many of these limitations in the future
with this ongoing global registry and welcome new partici-
pants to join us (https://note.reports.nl).
Conclusions
Initiation of NOACs and transition from VKA to NOACs
seem to be safe during the first month, without major adverse
events and with limited minor side effects in adults with CHD
and atrial arrhythmias. This global ongoing prospective regis-
try enables precise collection of important clinical information
in real-world adults with CHD, managed with NOACs.
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